Voyager Therapeutics (NASDAQ:VYGR) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday, ValuEngine reports.

A number of other research firms also recently commented on VYGR. Cowen reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a report on Monday, August 12th. Nomura reiterated a “buy” rating and issued a $37.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, August 13th. BidaskClub downgraded Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 27th. Finally, Zacks Investment Research upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Saturday, October 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $27.63.

NASDAQ VYGR traded up $0.38 during trading hours on Friday, hitting $14.86. 263,700 shares of the company were exchanged, compared to its average volume of 451,389. The company has a 50 day moving average of $15.86 and a two-hundred day moving average of $20.84. Voyager Therapeutics has a 52-week low of $7.76 and a 52-week high of $28.79. The firm has a market cap of $548.84 million, a price-to-earnings ratio of -5.40 and a beta of 2.58.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.42. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. The business had revenue of $20.43 million for the quarter, compared to the consensus estimate of $3.94 million. Equities analysts expect that Voyager Therapeutics will post -1.95 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $139,000. Tocqueville Asset Management L.P. boosted its position in shares of Voyager Therapeutics by 25.5% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 28,655 shares of the company’s stock valued at $493,000 after purchasing an additional 5,830 shares during the period. California Public Employees Retirement System boosted its position in shares of Voyager Therapeutics by 53.7% in the 3rd quarter. California Public Employees Retirement System now owns 11,728 shares of the company’s stock valued at $202,000 after purchasing an additional 4,100 shares during the period. Chicago Equity Partners LLC acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $400,000. Finally, First Quadrant L P CA boosted its position in shares of Voyager Therapeutics by 324.0% in the 3rd quarter. First Quadrant L P CA now owns 13,432 shares of the company’s stock valued at $231,000 after purchasing an additional 10,264 shares during the period. Institutional investors and hedge funds own 78.63% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.